- Report
- February 2024
- 70 Pages
Brazil
From €4593EUR$4,750USD£3,919GBP
- Report
- February 2024
- 70 Pages
Russia
From €4593EUR$4,750USD£3,919GBP
- Report
- February 2024
- 70 Pages
Australia
From €4593EUR$4,750USD£3,919GBP
- Report
- February 2024
- 70 Pages
China
From €4593EUR$4,750USD£3,919GBP
- Report
- February 2024
- 70 Pages
Japan
From €4593EUR$4,750USD£3,919GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4593EUR$4,750USD£3,919GBP
- Report
- October 2022
- 70 Pages
Africa
From €4593EUR$4,750USD£3,919GBP
- Report
- August 2020
- 150 Pages
Global
From €4109EUR$4,250USD£3,506GBP
- Report
- October 2019
- 125 Pages
Canada
From €4593EUR$4,750USD£3,919GBP
- Report
- February 2019
- 30 Pages
Global
From €9669EUR$10,000USD£8,250GBP
- Drug Pipelines
- February 2018
- 207 Pages
Global
From €21272EUR$22,000USD£18,149GBP
- Drug Pipelines
- February 2018
- 33 Pages
Global
From €9669EUR$10,000USD£8,250GBP
- Report
- February 2024
- 95 Pages
Global
From €3500EUR$3,878USD£3,091GBP
- Report
- February 2024
- 93 Pages
Global
From €3500EUR$3,878USD£3,091GBP
- Report
- May 2023
- 96 Pages
Global
From €3500EUR$3,878USD£3,091GBP
- Report
- April 2022
- 207 Pages
Global
From €1934EUR$2,000USD£1,650GBP
- Report
- April 2024
- 50 Pages
Global
From €2562EUR$2,650USD£2,186GBP
Canagliflozin is a medication used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It belongs to a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, which work by blocking the reabsorption of glucose in the kidneys, allowing it to be excreted in the urine. This helps to lower blood sugar levels. Canagliflozin is typically used in combination with other diabetes medications, such as metformin, to help control blood sugar levels.
Canagliflozin is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2013. It has become increasingly popular in recent years, as it is an effective treatment for type 2 diabetes and has fewer side effects than other diabetes medications.
The Canagliflozin market is an important part of the Endocrine and Metabolic Disorders Drugs market. It is a growing market, with more and more people being diagnosed with type 2 diabetes each year. As such, the demand for Canagliflozin and other SGLT2 inhibitors is expected to continue to rise.
Some companies in the Canagliflozin market include Johnson & Johnson, Merck, and AstraZeneca. Show Less Read more